PBAC's latest decision on Methadone: Recommended with restriction (2025). Considered for Chronic severe disabling pain and severe disabling pain in palliative care patients where alternative pain management therapies have failed.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adults with chronic severe disabling pain or severe disabling pain in palliative care who are not opioid-naïve and have had inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics, or are unable to use such analgesics due to contraindications or intolerance.
Therapy area
Pain
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
methadone 10 mg tablet (Physeptone)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis proposed; no ICER calculated.